Provention Bio Inc

PRVB

NASDAQ. Currency in USD

8.86 -0.42 ( -4.53% )

Real time prices: December 19

Market Cap.
772.51M
Beta (5Y monthly)
2.40
Price/Earnings
-
EPS (TTM)
-1.56
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.21M
1y Target Est.
18.38
Day's Range
8.79
-
9.35
52 Week's Range
3.19
-
10.14

Historical Summary

Performance
EPS growth
Share Buybacks

About Provention Bio Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.proventionbio.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
63.37M
Employees
82
Address
55 Broad Street, Red Bank, NJ, United States, 07701
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Latest news

Why Shares of Provention Bio Went Up 30.3% in November
Why Shares of Provention Bio Went Up 30.3% in November

The company got approval for its lead type 1 diabetes therapy.
By The Motley Fool - 7 weeks ago

Is This Biotech Stock a Buy Following a Landmark Approval?
Is This Biotech Stock a Buy Following a Landmark Approval?

You may not want to be too quick to pull the trigger.
By The Motley Fool - 8 weeks ago

Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday

Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after...
By Benzinga - 9 weeks ago

ConocoPhillips To Plunge Over 11%? Plus This Analyst Slashes PT On LiveOne By 25%
ConocoPhillips To Plunge Over 11%? Plus This Analyst Slashes PT On LiveOne By 25%

Societe Generale boosted the price target on ConocoPhillips (NYSE: COP) from $106 to $114. ConocoPhillips...
By Benzinga - 9 weeks ago

What 5 Analyst Ratings Have To Say About Provention Bio
What 5 Analyst Ratings Have To Say About Provention Bio

Over the past 3 months, 5 analysts have published their opinion on Provention Bio (NASDAQ:PRVB)...
By Benzinga - 10 weeks ago

Delta Apparel, Farfetch, American Software And Some Other Big Stocks Moving Lower On Friday
Delta Apparel, Farfetch, American Software And Some Other Big Stocks Moving Lower On Friday

U.S. stocks traded mixed, with the Dow Jones gaining more than 80 points on Friday....
By Benzinga - 10 weeks ago

Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset
Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset

Following FDA approval, Provention Bio's (PRVB) Tzield is the first disease-modifying therapy in T1D. Tzield...
By Zacks Investment Research - 10 weeks ago